There are currently 363 clinical trials in Stanford, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Stanford University, Stanford University School of Medicine, Stanford University Medical Center and Stanford Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616
Recruiting
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
05/06/2025
Locations: Stanford University - (Stanford Cancer Institute), Stanford, California
Conditions: Hodgkin Lymphoma
Register for Updates
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
NCT06517641
Recruiting
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Gender:
ALL
Ages:
Between 3 years and 75 years
Trial Updated:
05/06/2025
Locations: Stanford University, Stanford, California
Conditions: Severe Aplastic Anemia
Register for Updates
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
NCT05197920
Recruiting
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Stanford University, Stanford, California
Conditions: Acute Pancreatitis
Register for Updates
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
NCT04585490
Recruiting
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Stanford University, Stanford, California
Conditions: Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Register for Updates
Study of Aspirin in Patients With Vestibular Schwannoma
NCT03079999
Recruiting
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/05/2025
Locations: Stanford Otolaryngology/HNS, Stanford, California
Conditions: Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Register for Updates
Oxytocin Pharmacokinetics and Pharmacodynamics
NCT05488457
Recruiting
Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynam... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2025
Locations: Stanford University, Stanford, California
Conditions: Post Partum Hemorrhage, Cesarean Section Complications, Blood Loss
Register for Updates
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
NCT03964480
Recruiting
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Stanford University, Stanford, California
Conditions: Peripheral T-Cell Lymphoma
Register for Updates
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
NCT04840472
Recruiting
The primary purpose of the study is to assess the safety of 111In-panitumumab as a molecular imaging agent in patients with Head and Neck Squamous Cell Carcinoma. The secondary objective is to compare sensitivity and specificity of identifying sentinel lymph nodes by systemic injection of 111In-panitumumab prior to Day of Surgery versus conventional local injection with an optical dye at the time of surgery.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
05/02/2025
Locations: Stanford University, Stanford, California
Conditions: Head and Neck Cancer
Register for Updates
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT05987644
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California
Conditions: Lung Cancer, NSCLC, Brain Metastases
Register for Updates
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
NCT00373347
Recruiting
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Liver Cancer
Register for Updates
Leveraging Mindsets to Improve Health and Wellbeing in Patients With Cancer
NCT04020029
Recruiting
Primary Objectives: Mindsets have been rigorously studied in the domains of development, education, and more recently, in health and disease. However, there are no large-scale longitudinal studies of the mindsets held by cancer patients and how they may affect treatment outcomes, physical health, and psychological well-being. This randomized, single-blind, treatment-as-usual (TAU) control study aims to assess (1) mindsets at four time points spanning from the point of diagnosis to six weeks pos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University, Stanford, California
Conditions: Cancer
Register for Updates
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT01034033
Recruiting
The purpose of this study is to try to understand the biology of development of breast, ovarian, fallopian tube, peritoneal or endometrial cancer from persons at high genetic risk for these diseases. The influence of environmental factors on cancer development in individuals and families will be studied. The efficacy of treatments for these diseases will be evaluated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Ovarian Cancer, Gynecologic Cancers, Ovarian/Peritoneal/Fallopian Cancer
Register for Updates